AstraZenca

Recent Articles

• Sobrera, Recipharm Collaborate to Advance Alcohol Use Disorder Treatment
• Centaur Pharma launches WOXheal to treat diabetic foot ulcers
• FSD Pharma gets US FDA nod to begin phase 2 study of FSD201 to treat COVID-19
• AbbVie’s Elezanumab receives US FDA orphan drug and fast track designations
• USFDA granted expanded access to investigational ERK inhibitor ulixertinib
• Case Study – Strategic Insight on Gilead and Immunomedics $21 Billion Deal
• Insight on USFDA approval of pralsetinib to treat non-small lung cancer
• What is hybrid clinical trial?
• Strides Pharma to acquire 54% stake in SteriScience
• Aurobindo Pharma partners with BIRAC to develop Covid-19 vaccine
• Insight on First approved COVID-19 vaccine Sputnik V
• Novavax and Serum Institute of India – licensing agreement for Development and Commercial Collaboration
• Novavax reports positive results from phase 1 trial of COVID-19 vaccine candidate, NVX-CoV2373 with Matrix-M
• Lupin gets exclusive rights to market and distribute 2 complex injectable assets from ForDoz Pharma
• Biotricity receives US FDA 510(k) clearance for Bioflux software II system
• Cofsils brand expansion with face masks launch
• Zydus Cadila’s ZyCoV-D in Phase II clinical trials for COVID-19
• Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA
• Novavax, FDB agreement for large scale manufacturing of COVID-19 vaccine candidate
• Pfizer-BioNTech agreement with U.S. Gov for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2